5月15日，恒瑞医药（600276）正式启动H股全球公开发售，计划发行2.25亿股H股，发行价区间为每股 41.45—44.05港元，最高募资额可达130.8亿港元，或成为近五年港股医药板块最大规模IPO。据了解， 预计恒瑞医药最快于5月23日登陆港交所主板，实现"A+H"两地上市。新加坡政府投资公司(GIC)、景顺 (Invesco)、瑞银全球资产管理集团(UBS-GAM)等7家基石投资者已锁定近41亿港元认购额度，占发行规 模的43.04%。 恒瑞医药此次H股发行分为香港公开发售(5.5%)和国际配售(94.5%)，若全额行使超额配售权，总发行股 数可增至2.97亿股，募资上限达130.8亿港元。这意味着，此次恒瑞医药募资额将成为近五年港股医药企 业IPO最高募资额。招股书显示，募资净额将用于研发计划；在中国和海外市场建设新的生产和研发设 施，及扩大或升级在中国的现有生产设施；营运资金及其他一般企业用途等。 恒瑞医药此次IPO基石投资者阵容也十分豪华，吸引了众多市场化的国际知名投资机构的关注与参与， 包括新加坡政府投资公司(GIC)、景顺(Invesco)、瑞银全球资产管理集团(UBS-GAM)、高瓴资本 ...

Core Viewpoint - The company has demonstrated significant growth and profitability in 2024, achieving a revenue of 5.16 billion yuan and a net profit of 386 million yuan, driven by its "innovation + internationalization" strategy [1][2]. Group 1: Financial Performance - In 2024, the company reported a total revenue of 5.16 billion yuan, marking a year-on-year increase of 26.84% [1]. - The net profit attributable to shareholders reached 386 million yuan, successfully turning around from a loss [1]. - The pharmaceutical segment generated 4.26 billion yuan in revenue, accounting for 82.56% of total revenue, with a significant year-on-year growth [2]. Group 2: Product and Market Performance - The company's proprietary pharmaceutical products (including imports) achieved revenue of 3.66 billion yuan, a substantial increase of 50.64% year-on-year [2]. - In the domestic market, 30 proprietary products generated over 10 million yuan in sales, totaling 2.998 billion yuan, which is 95.16% of domestic proprietary revenue [2]. - The company’s international sales reached 735 million yuan, reflecting an 18.82% increase year-on-year, with 13 products exceeding 10 million yuan in sales [2]. Group 3: Innovation and R&D - The company has established a robust international R&D and production system, with its first large molecule innovative drug, Yili Shu, approved in multiple countries [3]. - Over the past decade, the company has invested 4.465 billion yuan in drug innovation and R&D [4]. - The company has 17 ongoing projects in traditional Chinese medicine and has completed 85 key milestones in small molecule drug development, a 13.3% increase from 2023 [5]. Group 4: Global Marketing and Future Strategy - The company has built a comprehensive marketing network, with 332 drug approvals in the domestic market and 43 product rights in international markets [6]. - The company plans to enhance its global presence by focusing on the U.S., Brazil, and Middle Eastern markets for its innovative products [7]. - In 2025, the company aims to deepen its focus on chronic diseases and expand its product offerings while optimizing its global production platform [8].